Randomized controlled trial comparing trimethoprim/sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients

The American Journal of Medicine

Volumn 76, Issue 2, 1984, Pages 223-233

  Bow, Eric J ^a   Louie, Thomas J ^a   Riben, Peter D ^a   McNaughton, R David ^a   Harding, Godfrey K M ^a   Ronald, Allan R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; NYSTATIN; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADVERSE DRUG REACTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CANDIDIASIS; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMPARISON; DRUG THERAPY; GRAM NEGATIVE BACTERIUM; GRANULOCYTOPENIA; HUMAN; INCIDENCE; INFECTION PREVENTION; LEUKEMIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PREVENTION; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; SUPERINFECTION; THERAPY;

ADULT; AGRANULOCYTOSIS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; DRUG COMBINATIONS; FECES; FEMALE; HUMANS; MALE; MYCOSES; NYSTATIN; PREMEDICATION; SULFAMETHOXAZOLE; TRIMETHOPRIM; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0021321816     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(84)90777-0     Document Type: Article

References (59)

1. Fever and infections in leukemic patients. A study of 494 consecutive patients
2. Causes of death in adults with acute leukemia
3. Infectious complications in the child with cancer. I. Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient
4. Infections during intensive chemotherapy for non-Hodgkin's lymphoma
5. Infections in patients with malignant lymphoma treated with combination chemotherapy
6. Infectious complications in leukemic patients
7. Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival
8. Haematologic malignancies and other marrow failure states: progress in the management of complicating infections
9. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens
10. Infection prevention during granulocytopenia
11. Infection prevention during profound granulocytopenia: new approaches to alimentary canal microbial suppression
12. Infection in acute nonlymphocytic leukemia: the alimentary tract as a major source of pathogens
13. Infection in acute leukemia patients receiving oral nonabsorbable antibiotics
14. Prevention of infection by trimethoprim/sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia
15. Relationship between colonization with pseudomonas aeruginosa to development of pseudomonas bacteremia in cancer patients
16. Gastrointestinal sterilization in the treatment of patients with acute leukemia
17. Prophylactic oral antibiotics in the management of acute leukaemia
18. Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia
19. Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia
20. Infection prevention in acute nonlymphocytic lemkemia. Laminar air flow room reverse isolation with oral nonabsorbable antibiotic prophylaxis
21. Colonization resistance of the digestive tract of mice during systemic antibiotic treatment
22. Selective suppression of alimentary tract microbial flora as prophylaxis during granulocytopenia
23. Successful chemoprophylaxis for pneumcystitis carinii pneumonitis
24. A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women
25. Prophylaxis of recurrent urinary tract infection in female patients. Efficacy of low-dose, thrice weekly therapy with trimethoprim-sulfamethoxazole
26. Prophylaxis of recurring urinary tract infection in females. A comparison of nitrofurantoin with trimethoprim/sulfamethoxazole
27. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract
28. A prospective controlled investigation of prophylactic trimethoprim/sulfamethoxazole in hospitalized granulocytopenic patients
29. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim/sulfamethoxazole vs. nalidixic acid
30. Cotrimoxazole versus nonabsorbable antibiotics in acute leukaemia
31. Co-trimoxazole for prevention of infection in acute leukaemia
32. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia
33. Co-trimoxazole alone for prevention of bacterial infection in patients with acute leukaemia
34. Cotrimoxazole and reduction of risk of infection in neutropenic patients
35. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo controlled trial
36. Trimethoprim/sulfamethoxazole versus placebo: a double-blind comparison of infection prophylaxis in patients with small cell carcinoma of the lung
37. Trimethoprim-sulfamethoxazole and trimethoprim alone for prophylaxis of infection in granulocytopenic patients
38. Comparative placebo controlled trial of oral vancomycin (v) plus gentamicin (G) and cotrimoxazole (c) for microbial suppression and prevention of infection in neutropenic cancer patients (abstr 333)
39. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients
40. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies
41. Adverse reactions to co-trimoxazole in hospitalized medical patients
42. Reduction in mortality from gram negative sepsis in neutropenic patients receiving trimethoprim/sulfamethoxazole therapy
43. Effect of trimethoprim, trimethoprimsulfamethoxazole and sulfamethoxazole on the occurrence of drug resistant Enterobacteriaceae in human bowel flora
44. Trimethoprim alone in the treatment and prophylaxis of urinary tract infection
45. Comparison of trimethoprim and trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients: elimination of potential pathogens and emergence of resistance
46. Non-Hodgkin's lymphoma in Manitoba, 1968–77: the impact of chemotherapy
47. Hematologic complications of cancer chemotherapy
48. Gastrointestinal toxicity of chemotherapeutic agents
49. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. A clinical-pathologic study of 33 patients
50. Prophylactic trimethoprim-sulfamethoxazole during consolidation chemotherapy for acute leukemia: a controlled trial
51. The effect of addition of colistin to the trimethoprim/sulfamethoxazole regimen for prevention of infection in acute nonlymphocytic leukaemia (abstr 93)
52. A haematologic study of patients receiving long term treatment with trimethoprim and sulfonamide
53. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole
54. Hematologic abnormalities after oral trimethoprim-sulfamethoxazole therapy in children
55. Trimethoprim-sulfamethoxazole therapy—everything's not turning up roses
56. Trimethoprim and sulfamethoxazole inhibition of haematopoiesis in vitro
57. Effects of trimethoprim on leukaemic cells in vitro
58. Resistance among fecal flora of patients taking sulfamethoxazole-trimethoprim or trimethoprim alone